Engineered immune cells take on hard-to-treat blood cancers in early trial
NCT ID NCT04684563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new cell therapy called huCART19-IL18 for people with CD19-positive blood cancers (like some leukemias and lymphomas) that have relapsed or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better target and attack cancer cells. The main goals are to check safety and find the best dose, with about 72 participants expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests